These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 33586169)

  • 1. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
    Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
    Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.
    Racey CS; Albert A; Donken R; Smith L; Spinelli JJ; Pedersen H; de Bruin P; Masaro C; Mitchell-Foster S; Sadarangani M; Dawar M; Krajden M; Naus M; van Niekerk D; Ogilvie G
    J Infect Dis; 2020 Jan; 221(1):81-90. PubMed ID: 31504649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.
    Goodman E; Reuschenbach M; Viering T; Luzak A; Greiner W; Hampl M; Jacob C
    Arch Gynecol Obstet; 2024 Nov; 310(5):2639-2646. PubMed ID: 39230793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
    Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
    J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
    Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
    Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
    Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
    Falcaro M; Soldan K; Ndlela B; Sasieni P
    BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
    McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
    Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.
    Brotherton JM; Fridman M; May CL; Chappell G; Saville AM; Gertig DM
    Lancet; 2011 Jun; 377(9783):2085-92. PubMed ID: 21684381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
    Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
    Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
    Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
    BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.